ClinicalTrials.gg
CompletedNCT01378286Updated Jul 18, 2013

Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria

A Phase 3 interventional study of ARTESUNATE + AMODIAQUINE and Chloroquine in Malaria, sponsored by Sanofi. Completed at 1 site in Brazil. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2013-07-18.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
6 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 68 studies testing artesunate in Malaria — none open to participants now, none under way, none of them phase 3. Artesunate · Malaria.

Enrollment
28th of 66
380 · median 290
Started
2012
with 5 others
Phase 3
17 of 68
none open now
Registered
45th of 68
by date
Lead sponsor
6 of 68
Sanofi

Among the 68 studies testing artesunate in Malaria, this one is the 28th largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2012, is one of 17 in phase 3, and was the 45th registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

None of the 68 studies testing artesunate in Malaria is open now. The open studies under Malaria, anywhere →

About artesunate

Artesunate: first FDA approval 2020 (ARTESUNATE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 6 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 68 studies testing artesunate in Malaria as a file.
02

Study summary

Primary Objective:

  • To demonstrate the non-inferiority of corrected adequate clinical and parasitological response at Day 28 of Artesunate Amodiaquine (ASAQ) versus chloroquine

Secondary Objectives:

  • To assess the non inferiority on the same way as the main criteria:
  • at Day 28 before corrected cure rate
  • at Day 14 and Day 42 before and after corrected cure rate
  • To compare the two groups of treatment in terms of:
  • Efficacy:

    • Proportion of aparasitaemic patients at 24, 48 an 72 hours
    • Proportion of afebrile patients at 24, 48 and 72 hours
    • Percentage of gametocyte carriers during follow-up
    • Evolution of the mean of gametocytes during the 42 days of follow-up
    • Evolution of haemoglobin value between Day 0 and Day 7, Day 0 and Day 28
  • Clinical and biological tolerability:

    • Proportion of any adverse event
    • Biological safety: haematology (Red blood cells, Haemoglobin, White Blood Cells, neutrophils, platelets), biochemistry (creatinine, transaminases (alanine amino transferase/ALT), bilirubins)
    • ECG (electro encephalogram) (Day 0, Day 3,Day 28) only for patients 10 years old and above
Read the detailed description

Each patient will be followed for a period of 42 days

03

Conditions studied

  • Malaria

Browse trials for

04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults and children over 6 months old and bodyweight > 5 kg
  • Able to be treated by oral route
  • Axillary temperature ≥ 37,5 C or history of fever during the previous 2 days
  • Symptomatic biologically confirmed Plasmodium vivax mono-infection, with parasitemia from 250 to 100000 parasites /µl of blood
  • Written of the patients and for children written informed consent of the parents/legal representative for children. Children able to understand the objectives and the risks of the study will sign an assent form.

Exclusion criteria

Exclusion criteria:

  • Known project of leaving the investigator site area during the follow-up period (42 days)
  • to one of the medicinal products or to any of the
  • Intake of an antimalarial treatment in the previous 30 days
  • History of hepatic and (or) haematological impairment during treatment with amodiaquine
  • Blurred vision suggesting a retinopathy
  • Presence of at least one danger sign of malaria
  • Pregnant or breast-feeding women
  • Women with not willing to use an effective method(s) for the duration of the study
  • Known severe concomitant or underlying disease

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    artesunate/amodiaquine

    artesunate (AS) / amodiaquine (AQ) as fixed dose combination 1 tablet of AS 25mg/ AQ 67,5mg or AS 50mg/AQ 135mg or AS 100mg/ AQ 270mg or 2 tablets of AS 100mg/ AQ 270mg dose according to bodyweight Once daily 3 days of treatment

    Drug: ARTESUNATE + AMODIAQUINE

  • Active comparator
    chloroquine

    150mg tablets 25mg/kg in 3 days (10mg/kg on day 1 and 7,5 mg/kg on days 2 and 3) dose according to bodyweight Once daily 3 days of treatment

    Drug: Chloroquine

Interventions

  • DrugARTESUNATE + AMODIAQUINE

    Drug pages: Artesunate · Amodiaquine

    Pharmaceutical form: Route of administration:

  • Pharmaceutical form:tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Assessment of clinical and parasitological efficacy based on temperature and parasitemia after Polymerase chain reaction (PCR) correction

    Time frame: 28 days

Secondary outcomes

  1. Assessment of clinical and parasitological efficacy based on temperature and parasitemia before and after PCR correction at D14 and D42 and before PCR correction at D28

    Time frame: up to a maximum of 42 days

  2. Number of patients without parasite

    Time frame: up to a maximum of 42 days

  3. Number of patients without fever

    Time frame: up to a maximum of 42 days

  4. Number of patients with gametocytes

    Time frame: up to a maximum of 42 days

  5. Change from baseline in Haemoglobin levels

    Time frame: Day 7, Day 28

  6. Incidence and severity of adverse events collected

    Time frame: up to a maximum of 42 days

  7. ECG (QTc) changes in patients group aged >= 10 years from baseline

    Time frame: Day 3, Day 28

  8. Assessment of biological tolerability (bilirubin, ALAT, Creatinine, Leukocytes, Neutrophils and platelets count) from baseline

    Time frame: up to a maximum of 42 days

07

Study locations

1 site
  • Administrative office
    Sao Paulo, Brazil
08

References and documents

Publications

  • Siqueira AM, Alencar AC, Melo GC, Magalhaes BL, Machado K, Alencar Filho AC, Kuehn A, Marques MM, Manso MC, Felger I, Vieira JL, Lameyre V, Daniel-Ribeiro CT, Lacerda MV. Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial. Clin Infect Dis. 2017 Jan 15;64(2):166-174. doi: 10.1093/cid/ciw706. Epub 2016 Oct 20. Erratum In: Clin Infect Dis. 2017 May 15;64(10):1468. doi: 10.1093/cid/ciw873. PubMed 27988484 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2011
First posted
Jun 22, 2011
Start
Jan 2012
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Last update
Jul 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01378286
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 22, 2011
Start date
Jan 2012
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Jul 18, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Artesunate · Amodiaquine

Start the discussion